Akira Endo, who discovered a “penicillin” for heart attacks (1933 to 2024)

Akira Endo, a scientist whose discovery saved millions of lives, died on June 5, 2024, at the age of 90.In 1972, while working as a biochemist at the Sankyo Pharmaceutical Company in Tokyo, Endo discovered a natural product that blocked the synthesis of cholesterol in animal cells.Isolated from a bluegreen mold, Endo's chemical was the first statin, a class of drugs that lower plasma cholesterol and prevent heart attacks.Ingested daily by more than 40 million Americans, statins rank with penicillin as among the most beneficial advances in human health.Born in 1933, Endo grew up on a farm in northern Japan.His interest in natural products was aroused when he read a biography of Alexander Fleming, who discovered penicillin, an antibacterial molecule produced by a blue-green mold.After graduating from Tohoku University in 1957, Endo joined the Sankyo Company as a biochemist.In the tradition of Fleming, Endo worked on a project that aimed to isolate useful products from molds.He was so successful that Sankyo provided a fellowship for him to study for two years in the United States.He was accepted into the laboratory of the noted biochemist Bernard Horecker at the Albert Einstein College of Medicine in New York.Although he had already developed an interest in cholesterol, this was not Horecker's interest, so Endo worked on enzymes involved in the synthesis of bacterial cell walls.Nevertheless, the training in enzymology was crucial to his future success in identifying the target of the first statin ( 1 ).Upon his return to Sankyo in 1968, Endo was given the rare opportunity to attack a pure science problem that had no immediate commercial application.Stimulated by the mounting evidence that high blood cholesterol causes heart attacks, Endo chose to search for an inhibitor of cholesterol synthesis.Over the previous two decades, the biochemists Konrad Bloch, Feodor Lynen, and John Cornforth had brilliantly elucidated the complex pathway by which organisms synthesize 27-carbon cholesterol from 2-carbon acetate.Of the 26 enzymatic steps in the pathway, the rate-limiting one had been identified as 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase), which catalyzes the first committed step.

Authors

Institutions

Publication Details

Journal
Proceedings of the National Academy of Sciences
Published
2024-09-19
DOI
https://doi.org/10.1073/pnas.2416550121
Primary Topic
Historical Medical Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Akira Endo, who discovered a “penicillin” for heart attacks (1933 to 2024)

Joseph L. Goldstein, Michael S. Brown
Proceedings of the National Academy of Sciences
Historical Medical Research and Treatments
article

Akira Endo, who discovered a “penicillin” for heart attacks (1933 to 2024)

Joseph L. Goldstein, Michael S. Brown
article en

Abstract

Akira Endo, a scientist whose discovery saved millions of lives, died on June 5, 2024, at the age of 90.In 1972, while working as a biochemist at the Sankyo Pharmaceutical Company in Tokyo, Endo discovered a natural product that blocked the synthesis of cholesterol in animal cells.Isolated from a bluegreen mold, Endo's chemical was the first statin, a class of drugs that lower plasma cholesterol and prevent heart attacks.Ingested daily by more than 40 million Americans, statins rank with penicillin as among the most beneficial advances in human health.Born in 1933, Endo grew up on a farm in northern Japan.His interest in natural products was aroused when he read a biography of Alexander Fleming, who discovered penicillin, an antibacterial molecule produced by a blue-green mold.After graduating from Tohoku University in 1957, Endo joined the Sankyo Company as a biochemist.In the tradition of Fleming, Endo worked on a project that aimed to isolate useful products from molds.He was so successful that Sankyo provided a fellowship for him to study for two years in the United States.He was accepted into the laboratory of the noted biochemist Bernard Horecker at the Albert Einstein College of Medicine in New York.Although he had already developed an interest in cholesterol, this was not Horecker's interest, so Endo worked on enzymes involved in the synthesis of bacterial cell walls.Nevertheless, the training in enzymology was crucial to his future success in identifying the target of the first statin ( 1 ).Upon his return to Sankyo in 1968, Endo was given the rare opportunity to attack a pure science problem that had no immediate commercial application.Stimulated by the mounting evidence that high blood cholesterol causes heart attacks, Endo chose to search for an inhibitor of cholesterol synthesis.Over the previous two decades, the biochemists Konrad Bloch, Feodor Lynen, and John Cornforth had brilliantly elucidated the complex pathway by which organisms synthesize 27-carbon cholesterol from 2-carbon acetate.Of the 26 enzymatic steps in the pathway, the rate-limiting one had been identified as 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase), which catalyzes the first committed step.

Proceedings of the National Academy of SciencesVol. 121(40)
The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 74%
Historical Medical Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.